With over two decades of experience , Dr Vedam Ramprasad has been with MedGenome Labs since its inception and spearheads operations and strategy . He has been a prime driver in building the diverse genetic testing portfolio offered by the company .
A scientist with several peer-reviewed publications to his credit , Dr Vedam Ramprasad believes in harnessing the power of genomics for providing a better outlook to patients . He is credited for launching some of the critical genetic tests at affordable price which include the Non-Invasive Pre-natal test ( NIPT ), Carrier screening test , and Liquid Biopsy to name a few . His commitment to adhere to the highest quality standards and processes has been instrumental in obtaining CAP accreditation for MedGenome .
As per Dr Vedam Ramprasad , his ultimate objective is to bring down the burden of healthcare that exists currently . “ It is possible if we are able to harness the power of genomics completely and mainstream that into our healthcare ecosystem . Globally , Genomics is a well-recognized field that fuels innovation not just in diagnosis but also in drug discovery . While India is steadily moving in that direction , collectively we need to acknowledge its potential and leverage upon the same ”, he says .
Dr Vedam Ramprasad was previously associated with Vision Research Foundation , Sankara Nethralaya , Spinco Biotech and
SciGenom labs . He holds a masters degree in human genetics from Osmania University and Ph . D in medical technology from BITS , Pilani .
For his unique contribution to make the genetic tests affordable and available in India , he was honored with the “ Healthcare leadership Award ” by ABP News in 2015 ). He was also a recipient of many other recognitions such as “ Start up 50 ” ( Smart CEO , 2019 ), and “ Top 25 Health Technology CEOs of India ”
Current Position : CEO , MedGenome Labs
Impact : A prime driver in building the diverse genetic testing portfolio offered by MedGenome .
Notable Awards : Healthcare leadership Award ” ( ABP News , 2015 ), “ Start up 50 ” ( Smart CEO , 2019 ), and “ Top 25 Health Technology CEOs of India
Alma Mater : BITS , Pliani ; Osmania University
( Health Technology Report , 2020 ).
Dr Vedam Ramprasad believes that there is an increase in the acceptance of genomics in several areas such as cancer and reproductive health . He explains : “ With more clinical evidence and scientific publications in these segments , there are lower apprehensions among the doctor and consumer community . Cancer genetic testing is estimated to witness high growth owing to increasing awareness about genetic tests for cancer treatment , increasing alignment for hereditary risk assessment and an alarming high rate of cancer incidence . Pharma majors are also looking at this space with great interest and investing in drugs and related companies to provide a more comprehensive portfolio of theranostic solutions .”
“ With drug resistance to the existing drugs lurking as a big scare , use of human genetics during drug development can help improve the rates of success in the trials phase . Several factors such as reduction in cost of these tests over time and possible public private partnership models is giving the usage of these tests a push ,” he informs .
HealthTech
BIOVOICENEWS . COM 27